Pioneering oral peptide therapy for patients with type 2 diabetes

Affiliations

¹ Diabetes Center Bochum-Hattingen, St. Josef-Hospital, Ruhr-University Bochum, D-44791 Bochum, Germany. Electronic address: michael.nauck@rub.de.
² Diabetes Center Bochum-Hattingen, St. Josef-Hospital, Ruhr-University Bochum, D-44791 Bochum, Germany.

Comment

Michael A Nauck et al. Lancet Diabetes Endocrinol. 2019 Jul.

. 2019 Jul;7(7):500-502.

doi: 10.1016/S2213-8587(19)30182-2. Epub 2019 Jun 9.

¹ Diabetes Center Bochum-Hattingen, St. Josef-Hospital, Ruhr-University Bochum, D-44791 Bochum, Germany. Electronic address: michael.nauck@rub.de.
² Diabetes Center Bochum-Hattingen, St. Josef-Hospital, Ruhr-University Bochum, D-44791 Bochum, Germany.

No abstract available

Comment on

Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial.
Mosenzon O, Blicher TM, Rosenlund S, Eriksson JW, Heller S, Hels OH, Pratley R, Sathyapalan T, Desouza C; PIONEER 5 Investigators. Mosenzon O, et al. Lancet Diabetes Endocrinol. 2019 Jul;7(7):515-527. doi: 10.1016/S2213-8587(19)30192-5. Epub 2019 Jun 9. Lancet Diabetes Endocrinol. 2019. PMID: 31189517 Clinical Trial.
Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial.
Pieber TR, Bode B, Mertens A, Cho YM, Christiansen E, Hertz CL, Wallenstein SOR, Buse JB; PIONEER 7 investigators. Pieber TR, et al. Lancet Diabetes Endocrinol. 2019 Jul;7(7):528-539. doi: 10.1016/S2213-8587(19)30194-9. Epub 2019 Jun 9. Lancet Diabetes Endocrinol. 2019. PMID: 31189520 Clinical Trial.